Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.J Clin Oncol 2004;22:1025–33

Phase Iii ◽

Cancer Center ◽

Phase Iii Trial ◽

Androgen Independent

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2004.07.005 ◽

2004 ◽

Vol 22 (5) ◽

pp. 433

Author(s):

Donald L. Trump

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

San Francisco ◽

Phase Iii ◽

Cancer Center ◽

Phase Iii Trial ◽

Androgen Independent

Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2013.08.012 ◽

2013 ◽

Vol 31 (8) ◽

pp. 1846

Author(s):

Donald L. Trump

Keyword(s):

Prostate Cancer ◽

San Francisco ◽

Metastatic Prostate Cancer ◽

Medical Oncology ◽

Cancer Center

Balmain, Prof. Allan, Barbara Bass Bakar Distinguished Professor of Cancer Genetics, University of California, San Francisco, since 2001; Co-Leader, Cancer Genetics Program, and Director, Genome Analysis Core Facility, UCSF Helen Diller Family Comprehensive Cancer Center

10.1093/ww/9780199540884.013.284097 ◽

2017 ◽

Keyword(s):

San Francisco ◽

Genome Analysis ◽

Cancer Genetics ◽

Cancer Center

582 CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS

The Journal of Urology ◽

10.1016/j.juro.2010.02.841 ◽

2010 ◽

Vol 183 (4S) ◽

Cited By ~ 2

Author(s):

Laurence Klotz ◽

Matthew Smith ◽

Bo-Eric Persson ◽

Tine Kold Olesen ◽

Arthur Wilde

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Cardiovascular Safety ◽

Open Label ◽

Phase Iii Trial ◽

Parallel Group

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2013.35 ◽

2013 ◽

Vol 16 (4) ◽

pp. 382-386 ◽

Cited By ~ 18

Author(s):

L A Kachnic ◽

S L Pugh ◽

P Tai ◽

M Smith ◽

E Gore ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Cancer Patients ◽

Phase Iii ◽

Phase Iii Trial ◽

Prevention Of Osteoporosis

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3-3 ◽

Cited By ~ 15

Author(s):

D. P. Petrylak ◽

C. Tangen ◽

M. Hussain ◽

P. N. Lara ◽

J. Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Androgen Independent

Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.9123 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 9123-9123 ◽

Cited By ~ 2

Author(s):

F. Joly ◽

G. Gravis ◽

S. Oudard ◽

M. Soulie ◽

B. Esterni ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Phase Iii ◽

Self Assessment ◽

Phase Iii Trial

Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4681 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4681-4681 ◽

Cited By ~ 1

Author(s):

I. Latorzeff ◽

B. Esterni ◽

M. Habibian ◽

G. Delplanque ◽

C. Theodore ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

The SAGE Encyclopedia of Cancer and Society ◽

10.4135/9781483345758.n598 ◽

2015 ◽

Keyword(s):

San Francisco ◽

Cancer Center

Ashworth, Prof. Alan, (born 26 Aug. 1960), President, Helen Diller Family Comprehensive Cancer Center, Professor of Medicine, Division of Hematology/Oncology, E. Dixon Heise Distinguished Professor in Oncology, and Senior Vice President for Cancer Services, University of California, San Francisco, since 2015

10.1093/ww/9780199540884.013.10000075 ◽

2007 ◽

Keyword(s):

San Francisco ◽

Vice President ◽

Cancer Center ◽

Senior Vice President ◽

Cancer Services